Ferguson to Issue Results for the Period Ended December 31, 2025, as well as provide an Update on Market Opportunities and Strategy on February 24, 2026
NEWPORT NEWS, Va.–(BUSINESS WIRE)–Ferguson Enterprises Inc. (NYSE: FERG; LSE: FERG) announces today that it will issue its results for the period ended... Read more.
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal... Read more.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent... Read more.
Chimera Increases First Quarter 2026 Common Stock Dividend to $0.45 and Declares First Quarter 2026 Preferred Stock Dividends
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.45 PER SHARE OF COMMON STOCK BOARD EXPECTS CHIMERA TO MAINTAIN A QUARTERLY DIVIDEND OF $0.45 PER COMMON SHARE FOR... Read more.
Partners Capital Closes $1+ Billion Merlin IV Co-Investment Fund, Strengthening Global Platform
BOSTON & LONDON–(BUSINESS WIRE)–Partners Capital Investment Group (“Partners Capital”), a leading global investment firm with over $70 billion... Read more.
SharkNinja Reports Fourth Quarter and Full Year 2025 Results
Provides Fiscal Year 2026 Outlook Announces Inaugural $750 Million Share Repurchase Authorization NEEDHAM, Mass.–(BUSINESS WIRE)–SharkNinja, Inc. (“SharkNinja”... Read more.
Sandy Voss Joins Life Science Connect as Senior Vice President of Live Events
PITTSBURGH–(BUSINESS WIRE)–Life Science Connect (LSC), a network of life science go-to-work solutions, today announced the appointment of Sandy Voss... Read more.
NiSource Announces Full-Year 2025 Results
Achieved 2025 non-GAAP adjusted EPS above guidance range Exceeded 2025 non-GAAP FFO/Debt guidance range Reaffirming 2026 non-GAAP consolidated adjusted EPS guidance... Read more.
Wabtec Delivers Strong Fourth Quarter 2025 Results; Announces 2026 Full-Year Guidance
Multi-year backlog reaches another record at $27 Billion, up 23% versus prior year Full Year GAAP Earnings per Share of $6.83, up 13% & Adjusted Earnings per... Read more.
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeOne–BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report... Read more.